Are you offering PARP inhibitor alone or both PARP inhibitor and bevacizumab maintenance for HRD+ ovarian cancer patients after upfront treatment?

If already giving bevacizumab for tumor-related reasons at initial presentation, would continue to maintain and add parp inhibitor, however, otherwise would use avastin later at recurrence, typically.